---

To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.

 

Related Information

• FDA Drug Saftey Communication: FDA clarifies Warning about Pediatric Use of Revatio (sildenafil) for Pulmonary Arterial Hypertension
• FDA Drug Safety Communication: FDA recommends against use of Revatio in children with pulmonary hypertension
• Comunicado de la FDA sobre la seguridad de los medicamentos La FDA recomienda que no se use Revatio en niños con hipertensión pulmonary

Regulatory History and Labeling from Drugs@FDA

• Regulatory History of Sildenafil